Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 19/20 | 1.00 |
| ▸ | PTPN2 | P17706 | 8/20 | 1.00 |
| ▸ | PTPRC | P08575 | 3/20 | 1.00 |
| ▸ | PTPRB | P23467 | 2/20 | 0.65 |
| ▸ | PTPRE | P23469 | 2/20 | 0.65 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.65 |
| ▸ | PTPRA | P18433 | 3/20 | 0.60 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20542250 | 0.99 | PTPN1 (0.97) | PTPN1PTPN2PTPRCPTPRBPTPRE | |
| SCHEMBL7534829 | 0.87 | PTPN1 (0.76) | PTPN1PTPN2PTPRCPTPRBPTPRE | |
| SCHEMBL13832367 | 0.86 | PTPN1 (0.75) | PTPN1PTPN2PTPRCPTPRBPTPRE | |
| SCHEMBL4080558 | 0.80 | PTPN1 (0.67) | PTPN1PTPN2PTPRCPTPRBPTPRE | |
| SCHEMBL5837972 | 0.79 | PTPN1 (1.00) | PTPN1PTPN2PTPRCPTPRBPTPRE | |
| SCHEMBL13810695 | 0.78 | PTPN1 (0.63) | PTPN1PTPN2PTPRCPTPRBPTPRE | |
| SCHEMBL22372483 | 0.75 | PTPN1 (1.00) | PTPN1PTPN2PTPRCPTPRBPTPRE | |
| SCHEMBL6315134 | 0.75 | PTPN1 (1.00) | PTPN1PTPN2PTPRCPTPRBPTPRE | |
| SCHEMBL30772840 | 0.75 | PTPRC (0.60) | PTPN1PTPN2PTPRCCXCR2 | |
| SCHEMBL4312414 | 0.74 | PTPN1 (1.00) | PTPN1PTPN2PTPRCPTPRBPTPRE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230114123-A1 | METHOD OF STIMULATING ASYMMETRIC DIVISION OF SATELLITE STEM CELLS | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2023-04-13 | — | — | US | claimed |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2022-03-03 | — | — | US | claimed |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LINK THERAPEUTICS, LLC | 2021-10-21 | — | — | US | claimed |
| EP-3612195-A1 | A METHOD OF STIMULATING ASYMMETRIC DIVISION OF SATELLITE STEM CELLS | Ottawa Hospital Research Institute (CA) | 2020-02-26 | — | — | EP | claimed |
| US-20200038485-A1 | METHOD OF STIMULATING ASYMMETRIC DIVISION OF SATELLITE STEM CELLS | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2020-02-06 | — | — | US | claimed |
| WO-2018195046-A1 | A METHOD OF STIMULATING ASYMMETRIC DIVISION OF SATELLITE STEM CELLS | OTTAWA HOSPITAL RESEARCH INSTITUTE (CA) | 2018-10-25 | — | — | WO | claimed |
| EP-1080095-B1 | MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPASES) | NOVO NORDISK AS (DK) | 2005-11-02 | — | — | EP | claimed |
| US-20030069267-A1 | Modulators of protein tyrosine phosphatases (PTPases) | MOLLER NIELS PETER HUNDAHL (DK) | 2003-04-10 | — | — | US | claimed |
| US-6262044-B1 | CONTAINING AN AMIDE-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE RING | NOVO NORDISK A/S (DK) | 2001-07-17 | — | — | US | claimed |
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | LINK THERAPEUTICS, LLC | 2025-10-07 | — | — | US | disclosed |
| US-12297234-B2 | Genetically encoded system for constructing and detecting biologically active agents | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250034551-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT BIOCHEMICAL SCREENS | NATIONAL SCIENCE FOUNDATION | 2025-01-30 | — | — | US | disclosed |
| EP-4426882-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT BIOCHEMICAL SCREENS | Think Bioscience, Inc. (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20240199704-A1 | GENETICALLY ENCODED SYSTEM FOR CONSTRUCTING AND DETECTING BIOLOGICALLY ACTIVE AGENTS | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2024-06-20 | — | — | US | disclosed |
| WO-2005033102-A2 | THIOPHENE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMPHORA DISCOVERY CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
| US-20030069267-A1 | Modulators of protein tyrosine phosphatases (PTPases) | MOLLER NIELS PETER HUNDAHL (DK) | 2003-04-10 | — | — | US | disclosed |
| US-6410586-B1 | ANTICOAGULANTS; INSULIN RESISTANCE; ANTIALLERGENS | NOVO NORDISK A/S (DK) | 2002-06-25 | — | — | US | disclosed |
| EP-1214060-A2 | METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2002-06-19 | — | — | EP | disclosed |
| US-6262044-B1 | CONTAINING AN AMIDE-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE RING | NOVO NORDISK A/S (DK) | 2001-07-17 | — | — | US | disclosed |
| WO-2001017516-A2 | METHOD OF INHIBITING PROTEIN TYROSINE PHOSPHATASE 1B AND/OR T-CELL PROTEIN TYROSINE PHOSPHATASE AND/OR OTHER PTPASES WITH AN ASP RESIDUE AT POSITION 48 | NOVO NORDISK A/S (DK) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069267-A1 | Modulators of protein tyrosine phosphatases (PTPases) | PTPRCAP, PTPRS, PTPRA | PTPN1 7/4885PTPN2 9/4885PTPRC 6/4885 |
| US-12435116-B2 | Compounds, compositions, methods, and uses for treating insulin resistance, type 2 diabetes and metabolic syndrome | INSR, IRS1, INSRR | PTPN1 1498/4885PTPN2 775/4885PTPRC 779/4885 |
| US-20210324031-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING LEPTIN RESISTANCE, OBESITY, DIABETES MELLITUS AND METABOLIC SYNDROME | LIPE, GPR119, FABP4 | PTPN1 1137/4885PTPN2 1382/4885PTPRC 258/4885 |
| US-20220064249-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING INSULIN RESISTANCE, TYPE 2 DIABETES AND METABOLIC SYNDROME | INSR, IRS1, INSRR | PTPN1 1498/4885PTPN2 775/4885PTPRC 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.